

Resource Summary Report

Generated by [RRID](#) on Jul 29, 2026

B6.Cg-Tg(Tyr-cre/ERT2)13Bos Braf^{tm1Mmcm} Pten/BosJ

RRID:IMSR_JAX:013590

Type: Organism

Proper Citation

RRID:IMSR_JAX:013590

Organism Information

URL: <https://www.jax.org/strain/013590>

Proper Citation: RRID:IMSR_JAX:013590

Description: Mus musculus with name B6.Cg-Tg(Tyr-cre/ERT2)13Bos Braf^{tm1Mmcm} Pten/BosJ from IMSR.

Species: Mus musculus

Synonyms: B6.Cg-Braf Pten Tg(Tyr-cre/ERT2)13Bos/BosJ

Notes: gene symbol note: transgene insertion 13; Marcus Bosenberg|B-Raf proto-oncogene; serine/threonine kinase|tyrosinase|phosphatase and tensin homolog; mutant strain|congenic strain: Tg(Tyr-cre/ERT2)13Bos|Braf|Tyr|BRAF|Pten|

Affected Gene: transgene insertion 13; Marcus Bosenberg|B-Raf proto-oncogene; serine/threonine kinase|tyrosinase|phosphatase and tensin homolog|

Genomic Alteration: transgene insertion 13; Marcus Bosenberg|targeted mutation 1; Martin McMahon|targeted mutation 1; Hong Wu

Catalog Number: JAX:013590

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: B6.Cg-Tg(Tyr-cre/ERT2)13Bos Braf^{tm1Mmcm} Pten/BosJ

Record Creation Time: 20250513T053725+0000

Ratings and Alerts

No rating or validation information has been found for B6.Cg-Tg(Tyr-cre/ERT2)13Bos Braf^{tm1Mmcm} Pten/BosJ.

No alerts have been found for B6.Cg-Tg(Tyr-cre/ERT2)13Bos Braf^{tm1Mmcm} Pten/BosJ.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhou Q, et al. (2025) Vorapaxar enhanced mitochondria-associated ferroptosis primes cancer immunotherapy via targeting FOXO1/HMOX1 axis. Cell reports. Medicine, 102371.

Mikheil D, et al. (2023) Notch Signaling Suppresses Melanoma Tumor Development in BRAF/Pten Mice. Cancers, 15(2).

Arumi-Planas M, et al. (2023) Microenvironmental Snail1-induced immunosuppression promotes melanoma growth. Oncogene, 42(36), 2659.

Meiser P, et al. (2023) A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunity. Cancer cell, 41(8), 1498.

Adaku N, et al. (2023) Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression and Metastasis. Cancer research, 83(18), 3013.

Reticker-Flynn NE, et al. (2022) Lymph node colonization induces tumor-immune tolerance to promote distant metastasis. Cell, 185(11), 1924.

Mu W, et al. (2021) Hypothalamic Rax+ tanycytes contribute to tissue repair and tumorigenesis upon oncogene activation in mice. Nature communications, 12(1), 2288.

DeVito NC, et al. (2021) Pharmacological Wnt ligand inhibition overcomes key tumor-mediated resistance pathways to anti-PD-1 immunotherapy. Cell reports, 35(5), 109071.

Le HH, et al. (2021) Molecular modelling of the FOXO4-TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells. EBioMedicine, 73, 103646.

Vitiello M, et al. (2019) Antitumoral effects of attenuated *Listeria monocytogenes* in a genetically engineered mouse model of melanoma. *Oncogene*, 38(19), 3756.

Millar MW, et al. (2018) The Adhesion G-Protein-Coupled Receptor, GPR56/ADGRG1, Inhibits Cell-Extracellular Matrix Signaling to Prevent Metastatic Melanoma Growth. *Frontiers in oncology*, 8, 8.

Zhao F, et al. (2018) Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGF β Inhibitor Sequencing in Melanoma. *Cancer immunology research*, 6(12), 1459.

Chen S, et al. (2017) Palmitoylation-dependent activation of MC1R prevents melanomagenesis. *Nature*, 549(7672), 399.

Spitzer MH, et al. (2017) Systemic Immunity Is Required for Effective Cancer Immunotherapy. *Cell*, 168(3), 487.

Riedel A, et al. (2016) Tumor-induced stromal reprogramming drives lymph node transformation. *Nature immunology*, 17(9), 1118.